3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow Epothilones: new trials by email Literature Review of Epothilones trials Research Report on Epothilones
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 3 | Completed | National Cancer Institute (NCI) | 799 | 2008-10-13 | 2026-06-23 |
| Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Ixabepilone + Capecitabine, Capecitabine - Cancer, Breast Cancer | Phase 3 | Completed | R-Pharm | 1221 | 2003-11-01 | 2020-11-02 |
| Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Ixabepilone + Capecitabine, Capecitabine - Breast Cancer, Metastases | Phase 3 | Completed | R-Pharm | 752 | 2003-09-01 | 2020-11-02 |
Breast Neoplasms (3) · Neoplasm Metastasis (1) · Neoplasms (1)
R-Pharm (2) · National Cancer Institute (NCI) (1)
United States (3) · Argentina (2) · Belgium (2) · Brazil (2) · Canada (2) · China (2) · France (2) · Germany (2) · Greece (2) · Italy (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Australia (1)
Hope S Rugo (1)
PMID 21128114, PMID 21937232, PMID 24472478, PMID 17968020, PMID 26056183, PMID 28620884, PMID 29522361, PMID 34616010, PMID 39169033
U10CA031946 (1), U10CA180821 (1)